Condition: Solid Tumors Harboring NTRK Fusion · NTRK · NTRK Gene Fusion · Sponsor: Cullgen (Shanghai),Inc
The goal of this clinical trial is to learn about the safety of drug CG001419. It also learn if drug CG001419 works to treat in locally advanced/metastatic adult solid tumours with NTRK gene fusions, NTRK gene point mutations, and NTRK gene amplification or over expression. The main questions it aims to answer are: Phase1:To determind the Maximum Tolerated Dose (MTD) and/or Phase 2 Recommended Dose for Phase 2 (RP2D) of CG001419 administered orally to adult subjects with locally advanced/metastatic solid tumours. To establish the safety and tolerability profile of CG001419. Phase2:To evaluate the efficacy of CG001419 in adult subjects with locally advanced or metastatic solid tumours harbouring oncogenic NTRK fusions, mutations, amplifications or over expression. Participants will Receive treatment with CG001419 until disease progression.
This description comes directly from the study's public registry record.
Xiangyu Jin, MS · +86 13858065096 · xiangyu.jin@cullgen.com
Qiao Yi · qiao.yi@cullgen.com
Always discuss trial participation with your own doctor first.
| The Cancer Hospital, Chinese Academy of Medical Sciences | Beijing, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, China | Recruiting |
| Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou, China | Recruiting |
| The Sir Run Run Shaw Hospital, Affiliated to Zhejiang University School of Medicine | Hangzhou, China | Recruiting |
| Zhejiang Provincial Cancer Hospital | Hangzhou, China | Recruiting |
| Shanxi Provincial Cancer Hospital | Taiyuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07394374